webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Ladiratuzumab vedotin

  CAS No.: 1629760-29-7   Cat No.: BADC-01597 4.5  

Ladiratuzumab vedotin is an antibody-drug conjugate consisting of a humanized anti-LIV-1 IgG1 conjugated with monomethyl auristatin E (MMAE). Ladiratuzumab vedotin has the potential for the treatment of metastatic triple-negative breast cancer.

Ladiratuzumab vedotin

Structure of 1629760-29-7

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
Antibody-Drug Conjugates (ADCs)

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
SGN-LIV1A; Anti-LIV-1 ADC

Ladiratuzumab vedotin is an antibody-drug conjugate (ADC) that combines a monoclonal antibody targeting the protein trophoblast cell-surface antigen 2 (Trop-2) with the cytotoxic agent monomethyl auristatin E (MMAE). Trop-2 is a cell surface glycoprotein overexpressed in several cancers, including breast, ovarian, and gastric cancers. The antibody component of Ladiratuzumab vedotin selectively binds to Trop-2 on cancer cells, allowing the drug to be specifically delivered to tumor sites. Upon internalization, the MMAE payload is released, which inhibits microtubule polymerization, resulting in cell cycle arrest and cell death. This targeted delivery mechanism minimizes damage to healthy cells, reducing systemic toxicity compared to traditional chemotherapy.

A significant application of Ladiratuzumab vedotin is in the treatment of metastatic triple-negative breast cancer (TNBC). TNBC is an aggressive subtype of breast cancer that lacks targeted therapies due to the absence of estrogen, progesterone, and HER2 receptors. Because Trop-2 is frequently overexpressed in TNBC, Ladiratuzumab vedotin can specifically target these cancer cells. Clinical trials have shown that Ladiratuzumab vedotin can improve progression-free survival in patients with heavily pre-treated TNBC, offering a promising therapeutic option for patients who do not respond to conventional treatments.

Ladiratuzumab vedotin is also being evaluated for its potential in the treatment of other Trop-2-expressing cancers, including ovarian and bladder cancers. For ovarian cancer, where Trop-2 is often overexpressed, Ladiratuzumab vedotin could provide a novel treatment option for patients with relapsed or resistant disease. Similarly, for urothelial carcinoma (bladder cancer), which has high Trop-2 expression, this ADC could target and deliver MMAE directly to tumor cells, improving treatment efficacy while reducing off-target effects. Its ability to target Trop-2 in a variety of solid tumors makes Ladiratuzumab vedotin a promising candidate for broader oncological applications.

In addition to its monotherapy potential, Ladiratuzumab vedotin is being explored in combination with other cancer therapies to enhance its therapeutic effect. Researchers are investigating its use alongside immune checkpoint inhibitors, chemotherapy, and targeted agents to improve response rates and overcome resistance mechanisms. By combining Ladiratuzumab vedotin with other agents, the aim is to create a synergistic treatment approach that not only targets the cancer more effectively but also stimulates the immune system to mount a stronger response against the tumor. This approach could significantly benefit patients with advanced cancers, improving survival outcomes and quality of life.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Manufacturing Services ADC cGMP Manufacturing ADC Fill/Finish ADC Purification ADC Formulation Development Antibody–Drug Conjugate Solutions ADC Early Discovery ADC Process Development ADC Preclinical Studies

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Current Technical Development Trends in Antibody-Drug Conjugate (ADC) Drugs The Development History of ADC Drugs What are Antibody Drug Conjugates? New FDA-Approved ADC: Disitamab Vedotin for Bladder Cancer New ADC Drug for Lymphoma: Loncastuximab Tesirine Overview of Antibody-Drug Conjugate (ADC) Production Technologies ADC Drugs: Unlocking New Frontiers in Tumor Treatment How to Design A Good ADC Drug? Tivdak: FDA's First Approved Tissue Factor-Targeted Antibody-Drug Conjugate How Endocytosis Influences the Receptor Targeting Mechanism of ADC Drugs?

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Ladiratuzumab vedotin
Send Inquiry
Verification code
Inquiry Basket